Benzinga | May 10, 2021 07:21AM EDT

KalVista Pharmaceuticals To Present Clinical Data Of KVD900 For The Oral Treatment Of Hereditary Angioedema At The 12th C1-Inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced acceptance of an abstract for KVD900 as an oral presentation at the 12th C1-Inhibitor Deficiency & Angioedema Workshop, which will be held virtually from June 3-6, 2021.